SPAC Presentation

Procaps at a Glance Track Record of Strong Growth, Margin Expansion and High ROIC Outstanding Net Revenue Growth USD mm 337 2019A 22% 73 14% CAGR¹ 2019A 329 2020A Strong Adjusted EBITDA³ Evolution Expanding Profitability USD mm Net Revenues / Adj. EBITDA (%) 27% 2 24% CAGR ¹ 90 2020A 397 9% CAGR Including FX Impact 2021E 26% 105 20% CAGR Including FX Impact 2021E Robust Adjusted EBITDA Growth USD mm 90 Adj. EBITDA 2020A ▪ Catalent Average: 17% 5 5% CDMO Business I 20 ■ Existing Portfolio Leading Capital Returns vs. Comps Universe Medians Genomma Lab Perrigo Hypera 8% 16% Organic Growth OTC Products 8 New Products ▪ Sun Pharma ▪ Dr. Reddy's I ■ Cipla Lupin ▪ Hikma Blau Farma. 10% (14) Pharma Companies G&A PROCAPS 23% PROCAPS, 105 Adj. EBITDA 2021E GROUP Return on invested capital, 2020 ▪ Novo Nordisk 43% Diabetes Solutions * Source: Capital IQ, Forbes, Bloomberg, public information from the companies and Procaps analysis Note: (1) Constant Prices 2020 (AOP); (2) In 2020, the Company implemented a strategic plan to reduce the number of trade days by deliberately drawing down the amount billed to distributors. While sales decreased to adjust the inventory levels, the growth trend with the final consumer is trending positively; (3) Adjusted by Severance & Other Non-Recurring Items, One-Time Trade Days Stabilization Impact, Synergies & Cost Savings and COVID Expenses; (4) ROIC = ((EBIT) x (1 - eff. tax rate)) / (fixed assets + intangible assets + WK (exc. cash-like items)); (5) Market avg. excludes Procaps 13

View entire presentation